Takeaways: This approval strengthens Lilly’s competitive stance against other GLP-1/GIP agents in the obesity space by adding a disease-specific indication (OSA) that ties directl...
Takeaways: Novo Nordisk’s updated Rybelsus in Canada is a smaller-tablet, lower-milligram GLP-1 formulation that delivers the same clinical effect as the original 3/7/14 mg doses, with 1.5/4/9 m...
